Live Breaking News & Updates on அல் ஓல அப்டால்லாஹ்
Stay updated with breaking news from அல் ஓல அப்டால்லாஹ். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
the recent brought together three expert leaders in their field: moderator Vinay Prasad, MD, is joined by Aaron Goodman, MD, and Al-Ola Abdallah, MD, for a virtual roundtable discussion on the new and potentially practice-changing data from the meeting. In episode one, the physicians debated the follow-up analysis of a trial that questioned the necessity of early versus delayed ASCT, in light of newer therapies we have today. In episode two, Dr. Prasad asked if selinexor, recently approved with support from the phase III BOSTON study, a good drug for the treatment of adults with multiple myeloma who have received at least one prior therapy? ....
Following is a transcript of their remarks: Vinay Prasad, MD: I m back with Aaron Goodman and Al-Ola Abdallah, and we re talking about ASH abstracts. Gentlemen, the myeloma field is excited about CAR-T or cellular therapy and they are going after all sorts of targets. Of course, they start with BCMA [B-cell maturation antigen], but they ve expanded from there, and CAR-T therapies are incredibly exciting. Those of us who ve used them in lymphoma, who have seen the ability to take a chemo-resistant patient and render them free of disease, folks who have used them in pediatric ALL [acute lymphocytic leukemia] have seen the impressive powers of CAR-T. It is not an easy therapy to administer. Often side effects are profound, including neurotoxicity. ....
Following is a transcript of their remarks: Vinay Prasad, MD: I m back with Dr. Aaron Goodman and Dr. Al-Ola Abdallah and we re talking about ASH and multiple myeloma. We have an exciting study to discuss, the FORTE study. This is a three-arm study that looks at carfilzomib-containing regimens, which, to my knowledge, is not the official standard of care in multiple myeloma in the frontline setting, although some believe it plays a role, and they ask a very provocative question about the role of transplant and maintenance. Dr. Goodman, I wonder if you might summarize the FORTE study. What is going on in FORTE, what are we finding, and what should we be thinking about? ....
Following is a transcript of their remarks: Vinay Prasad, MD: I m back with Aaron Goodman and Dr. Al-Ola Abdallah and we re talking about selinexor. Aaron, selinexor, good drug or great drug? How would you characterize this drug? Aaron Goodman, MD: I would characterize it as an awful drug. Prasad: Awful drug? Prasad: And why is that, sir? Goodman: Well, $2,200 to $4,000 a month, so it s clearly not cheap, yet to date there is no data that it makes the patients live longer and the toxicity profile, I would say, is not favorable. The drug company would like to remind us that it does have a novel mechanism. That s about it to me. ....
Following is a transcript of their remarks: Vinay Prasad, MD: All right, I m Dr. Vinay Prasad. I m an associate professor and a practicing hematologist oncologist here at the University of California San Francisco. I m joined via Zoom by two dear colleagues who are myeloma experts, Aaron Goodman, assistant professor at the University of California San Diego, an expert in bone marrow transplantation and hem malignancies, and Dr. Al-Ola Abdallah at the University of Kansas, also an expert in hematologic malignancies and bone marrow transplant. It s a pleasure to have you both here, sirs. Well, let s get started. There is so much to talk about at this year s ASH annual meeting about myeloma. All our favorite drugs are there and some of the ones we don t like too much, and so let s get started. ....